Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 5Ovarian Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Neoplasms 3Insulin-Like Growth Factor I, Resistance To 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Lymphoma 2Colonic Neoplasms 2Carcinoid Tumor 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Vincristine 3Radiotherapy 3Radiation 3Dactinomycin 3Cyclophosphamide 3Vinorelbine 2Magnetic Resonance Spectroscopy 2Biopsy 2temsirolimus 1ganitumab 1efineptakin alfa 1dinutuximab 1X-Rays 1Specimen Handling 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Phantoms, Imaging 1Irinotecan 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rhabdomyosarcoma, Embryonal × ganitumab × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡